How Much Does Tirosint Cost in Kansas in 2026?

Retail and Cash-Pay Pricing for Tirosint in Kansas

The average cash-pay price for brand-name Tirosint at Kansas retail pharmacies is approximately $230 per month in 2026, matching the manufacturer list price set by IBSA, the drug's maker. This price applies to a 30-count supply of gel capsules across standard dosage strengths (13 mcg through 200 mcg).

Prices at individual Kansas pharmacies vary. Large chain pharmacies such as CVS, Walgreens, and Walmart locations in Wichita, Overland Park, Kansas City (KS), and Topeka tend to cluster near the $230 figure for cash-pay customers. Independent pharmacies may price slightly higher or lower. Tirosint-SOL, the liquid formulation, can run $10 to $30 more per month than gel capsules at some locations.

Tirosint contains only four ingredients: levothyroxine sodium, gelatin, glycerin, and water 1. That minimal excipient profile is the reason clinicians prescribe it over standard levothyroxine tablets for patients with absorption issues. A 2014 study by Vita et al. in Endocrine (N=34) demonstrated that the gel capsule formulation achieved therapeutic TSH levels in patients with documented malabsorption who had failed standard levothyroxine tablets, including those taking proton pump inhibitors 2. The American Thyroid Association (ATA) 2014 guidelines acknowledge that liquid or gel cap levothyroxine formulations may benefit patients with absorption difficulties, particularly those with celiac disease, lactose intolerance, or concurrent PPI use 3.

The cost premium over generic levothyroxine tablets is substantial. Generic levothyroxine (Synthroid equivalents) costs $4 to $15 per month at most Kansas pharmacies. That price gap of roughly $215 per month makes coverage status and discount strategies essential for Kansas patients prescribed Tirosint.

Kansas Medicaid Coverage: Not Available for Hypothyroidism

Kansas Medicaid (KanCare) does not cover Tirosint for standard hypothyroidism management as of 2026. The Kansas Medicaid preferred drug list restricts brand-name thyroid medications, and Tirosint is classified as non-preferred without an established pathway for hypothyroidism-specific prior authorization.

This exclusion affects roughly 415,000 Kansans enrolled in KanCare managed care plans administered through Aetna Better Health, Sunflower Health Plan, and UnitedHealthcare Community Plan 4. If a prescriber believes Tirosint is medically necessary (for example, documented malabsorption on standard levothyroxine), the prescriber can submit a prior authorization request. Approvals are rare. Kansas Medicaid has historically cited the availability of generic levothyroxine as a therapeutically equivalent alternative.

For KanCare enrollees who cannot tolerate standard tablets, compounded levothyroxine through a 503A pharmacy represents the most cost-effective alternative. Kansas Medicaid may cover compounded prescriptions when a commercial equivalent is not on formulary, though coverage requires individual review.

The Centers for Medicare & Medicaid Services (CMS) reported that state Medicaid programs covered approximately 72% of all levothyroxine prescriptions nationally in 2024, but brand-name formulations like Tirosint accounted for less than 3% of those fills 5.

Commercial Insurance Coverage in Kansas

Most Kansas commercial insurers will cover Tirosint, though prior authorization is nearly universal. Blue Cross and Blue Shield of Kansas (BCBSKS), Aetna, UnitedHealthcare, and Cigna all list Tirosint on their formularies at Tier 3 (non-preferred brand) or Tier 4 (specialty), depending on the specific plan.

Prior authorization criteria typically require documentation of at least one of the following: failure or intolerance of generic levothyroxine tablets, a diagnosis of malabsorption (celiac disease, short bowel syndrome, or gastric bypass), concurrent use of medications known to interfere with levothyroxine absorption (PPIs, calcium, iron supplements), or persistent TSH elevation despite adherence to standard levothyroxine at adequate doses.

Copay amounts for Tier 3 coverage in Kansas range from $40 to $75 per month. Tier 4 placement can push copays to $100 to $150. Some high-deductible health plans (HDHPs) require patients to pay the full $230 until meeting their deductible.

The ATA's 2014 clinical practice guidelines for hypothyroidism note that "levothyroxine should be taken on an empty stomach, 30 to 60 minutes before breakfast, or at bedtime, 3 or more hours after the evening meal" and that gel cap formulations may be considered when absorption is compromised 3. This guideline language is often cited verbatim in prior authorization requests to support Tirosint coverage.

Dr. Antonio Bianco, a professor of medicine at the University of Chicago and past president of the American Thyroid Association, has stated: "There is a subset of patients who do not achieve adequate levothyroxine absorption from standard tablets, and alternative formulations like gel capsules offer a documented therapeutic advantage in those cases" 6.

IBSA Savings Card and Manufacturer Discounts

IBSA, the manufacturer of Tirosint, offers a copay savings card that can reduce the monthly cost to as little as $0 for commercially insured patients and $25 for cash-pay patients. The card is accepted at all major Kansas pharmacies.

Eligibility requirements: patients must have a valid Tirosint prescription, must not be enrolled in any federal healthcare program (Medicare, Medicaid, Tricare, VA), and must be a resident of the United States. Kansas patients who meet these criteria can enroll online or by calling IBSA's patient support line.

The savings card covers up to a specified maximum annual benefit. For 2026, the cap is typically $3,000 to $3,600 per year, which fully offsets the $230 monthly retail price for most of the calendar year. Patients should verify the current annual maximum at enrollment.

Three practical steps for Kansas patients:

1. Ask the prescriber to write the prescription specifically for Tirosint (not generic levothyroxine) so the pharmacy dispenses the brand product.
2. Present the IBSA savings card at the pharmacy along with any commercial insurance card.
3. If the pharmacy does not have Tirosint in stock, request a direct order. Most Kansas wholesalers (McKesson, AmerisourceBergen) carry Tirosint with next-day delivery.

Compounded Levothyroxine in Kansas: Legal and Available

Compounded levothyroxine in gel capsule or liquid form is legal in Kansas through licensed 503A compounding pharmacies. The Kansas State Board of Pharmacy regulates compounding under K.S.A. 65-1637 and follows FDA guidance under Section 503A of the Federal Food, Drug, and Cosmetic Act 7.

Compounded levothyroxine offers a significant cost advantage. Kansas 503A pharmacies typically charge $30 to $50 per month for a compounded gel cap or liquid levothyroxine preparation. Some telehealth platforms that partner with compounding pharmacies offer even lower pricing, sometimes below $30 per month with subscription models.

There are trade-offs. Compounded medications do not undergo the same bioequivalence testing as FDA-approved products. The FDA has issued multiple warnings about potency variability in compounded thyroid preparations 8. A 2004 analysis published in Thyroid found that compounded levothyroxine preparations from multiple pharmacies showed potency ranging from 59% to 172% of the labeled dose 9.

Dr. Jacqueline Jonklaas, professor of medicine at Georgetown University Medical Center and a co-author of the ATA hypothyroidism guidelines, has noted: "Patients who use compounded thyroid hormone preparations should have their TSH monitored more frequently, ideally every 6 to 8 weeks after any change in compounding pharmacy or formulation, to confirm consistent potency" 3.

For Kansas patients considering compounded levothyroxine, choosing a 503A pharmacy that holds PCAB (Pharmacy Compounding Accreditation Board) accreditation provides an additional layer of quality assurance. As of 2026, Kansas has several PCAB-accredited compounding pharmacies in the Wichita and Kansas City metropolitan areas.

Telehealth Prescribing of Tirosint in Kansas

Kansas permits telehealth prescribing of Tirosint. The Kansas Telemedicine Act (K.S.A. 40-2,215) allows licensed physicians to prescribe medications, including brand-name levothyroxine formulations, via telemedicine visits without requiring an initial in-person encounter 10.

This opens several pathways for Kansas patients:

Telehealth endocrinology platforms can evaluate thyroid labs, review prior treatment history, and prescribe Tirosint. Some platforms partner with compounding pharmacies to offer compounded levothyroxine at lower cost. A typical telehealth thyroid consultation runs $75 to $150 without insurance, and many Kansas commercial plans now cover telehealth visits at the same copay as in-person visits.

For patients in rural Kansas counties where endocrinology access is limited (79 of the state's 105 counties have no practicing endocrinologist according to the Association of American Medical Colleges 2023 workforce data 11), telehealth removes a geographic barrier to obtaining specialized thyroid care and brand-name prescriptions.

The prescribing clinician must hold an active Kansas medical license or practice under the Interstate Medical Licensure Compact, of which Kansas is a member state.

Discount Programs and Coupon Strategies

Beyond the IBSA savings card, Kansas patients have several additional options to reduce Tirosint costs.

GoodRx, RxSaver, and similar prescription discount platforms list Tirosint coupons that can bring cash-pay prices to $180 to $210 per month at select Kansas pharmacies. These savings are modest compared to the IBSA card but can help patients ineligible for manufacturer programs.

Medicare Part D enrollees, who cannot use the IBSA savings card, should compare formulary placement across Kansas Medicare Advantage and Part D plans during open enrollment. Some plans place Tirosint at Tier 3 with copays of $47 to $90 per month. The Medicare Plan Finder tool at medicare.gov allows Kansas residents to search by drug name and zip code.

Patient assistance programs (PAPs) exist for uninsured or underinsured patients. IBSA's own PAP provides free Tirosint to qualifying patients with household incomes below 300% of the federal poverty level. For a single-person household in 2026, that threshold is approximately $46,800 per year based on HHS poverty guidelines 12.

Kansas patients enrolled in the state's Medically Needy spend-down program may also qualify for Tirosint coverage once their incurred medical expenses reach the spend-down threshold, though this pathway is administratively burdensome and inconsistently applied across Kansas counties.

When Tirosint Is Worth the Premium Over Generic Levothyroxine

The $215 per month price gap between Tirosint and generic levothyroxine tablets raises a direct clinical question. The evidence supports Tirosint's use in specific populations, not as a general replacement for tablets.

Patients who benefit most from the gel capsule formulation include those with documented malabsorption syndromes (celiac disease prevalence: approximately 1% of the U.S. population per a 2012 study in the American Journal of Gastroenterology, N=7,798 13), post-bariatric surgery patients (Roux-en-Y gastric bypass reduces levothyroxine absorption by an estimated 25-50% per a 2013 Obesity Surgery study 14), and patients on concurrent PPIs, calcium, or iron supplements that interfere with tablet dissolution.

Vita et al. demonstrated in their 2014 Endocrine study that switching malabsorbing patients from standard levothyroxine tablets to gel capsules normalized TSH within 8 weeks in 88% of subjects without dose adjustment 2. That result suggests the absorption difference is clinically meaningful, not just a pharmacokinetic curiosity.

For patients without absorption issues, the ATA guidelines do not recommend brand-name formulations over bioequivalent generics 3. Kansas patients and their prescribers should weigh documented clinical need against the monthly cost difference when deciding whether Tirosint, compounded levothyroxine, or generic tablets represent the best fit.

A reasonable clinical benchmark: if a patient on generic levothyroxine requires two or more dose adjustments within 12 months due to unexplained TSH fluctuations, a trial of Tirosint or compounded gel cap levothyroxine is a defensible next step. Kansas prescribers can use this threshold to support prior authorization requests.